Polar Capital Global Healthcare Trust

Polar Capital Global Healthcare Trust
Polar Capital LLP
Closed Ended Investment Company
Sector Specialist: Biotechnology & Healthcare
1.13 %
Risk Rating
3 Year Sharpe
3 Year Alpha
0.8 %
Fund Size
£ 303.18 million
Discount Premium
The investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks across all four healthcare sub-sectors, being pharmaceuticals, biotechnology, medical technology and healthcare services.
Holding %
Roche Holding AG Dividend Right Cert. 4.91 %
UnitedHealth Group Inc 4.87 %
Medtronic PLC 4.81 %
Bristol-Myers Squibb Company 4.32 %
Thermo Fisher Scientific Inc 4.12 %
Fresenius Medical Care AG & Co. KGaA 4.09 %
Centene Corp 3.72 %
IQVIA Holdings Inc 3.65 %
Becton, Dickinson and Co 3.62 %
HCA Healthcare Inc 3.39 %
Region %
United States 75.60 %
Europe - ex Euro 10.11 %
Eurozone 9.19 %
Sector %
Healthcare 98.62 %
Polar Capital LLP
SW1E 5JD, London, United Kingdom
Legal Structure
Closed Ended Investment Company


James Douglas
Joined 04/30/2018

James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management.

Gareth Powell
Joined 06/15/2010

Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.